These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others. Bettiol E; Hackett J; Harbarth S J Law Med Ethics; 2018 Jun; 46(1_suppl):5-8. PubMed ID: 30146955 [TBL] [Abstract][Full Text] [Related]
24. Current Technology in the Discovery and Development of Novel Antibacterials. Chung PY Curr Drug Targets; 2018; 19(7):832-840. PubMed ID: 28891454 [TBL] [Abstract][Full Text] [Related]
25. The antibiotic pipeline: reviving research and development and speeding drugs to market. Luepke KH; Mohr JF Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360 [TBL] [Abstract][Full Text] [Related]
26. Few novel antibiotics in the pipeline, WHO warns. Kmietowicz Z BMJ; 2017 Sep; 358():j4339. PubMed ID: 28928155 [No Abstract] [Full Text] [Related]
27. [New antibiotics for the clinical setting, an overview]. Meylan S; Portillo Tunon V; Guery B Rev Med Suisse; 2020 Apr; 16(690):713-718. PubMed ID: 32301304 [TBL] [Abstract][Full Text] [Related]
28. Antibiotics in the clinical pipeline in 2011. Butler MS; Cooper MA J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262 [TBL] [Abstract][Full Text] [Related]
29. The economics of resistant pathogens and antibiotic innovation. McKellar MR; Chernew ME; Fendrick AM Am J Manag Care; 2014 Mar; 20(3):193-7. PubMed ID: 24884749 [No Abstract] [Full Text] [Related]
31. The CARB-X Portfolio of Nontraditional Antibacterial Products. Duffy EM; Buurman ET; Chiang SL; Cohen NR; Uria-Nickelsen M; Alm RA ACS Infect Dis; 2021 Aug; 7(8):2043-2049. PubMed ID: 34346202 [TBL] [Abstract][Full Text] [Related]
32. Discovery and development of new antibacterial drugs: learning from experience? Jackson N; Czaplewski L; Piddock LJV J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542 [TBL] [Abstract][Full Text] [Related]
33. Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. Tagliabue A; Rappuoli R Front Immunol; 2018; 9():1068. PubMed ID: 29910799 [TBL] [Abstract][Full Text] [Related]
34. The challenge of antimicrobial resistance: new regulatory tools to support product development. Tomayko JF; Rex JH; Tenero DM; Goldberger M; Eisenstein BI Clin Pharmacol Ther; 2014 Aug; 96(2):166-8. PubMed ID: 24823890 [TBL] [Abstract][Full Text] [Related]
35. What are the economic barriers of antibiotic R&D and how can we overcome them? Renwick M; Mossialos E Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625 [No Abstract] [Full Text] [Related]
36. The global need for effective antibiotics: challenges and recent advances. Högberg LD; Heddini A; Cars O Trends Pharmacol Sci; 2010 Nov; 31(11):509-15. PubMed ID: 20843562 [TBL] [Abstract][Full Text] [Related]
37. Is the GAIN Act a turning point in new antibiotic discovery? Brown ED Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332 [TBL] [Abstract][Full Text] [Related]
38. Genomic tools to profile antibiotic mode of action. Cardona ST; Selin C; Gislason AS Crit Rev Microbiol; 2015; 41(4):465-72. PubMed ID: 24617440 [TBL] [Abstract][Full Text] [Related]
39. Research and development of antibiotics: insights from patents and citation network. Zhang M; Kong X; Zheng J; Wan JB; Wang Y; Hu Y; Shao R Expert Opin Ther Pat; 2016 May; 26(5):617-27. PubMed ID: 26986226 [TBL] [Abstract][Full Text] [Related]
40. Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against Staphylococcus aureus and Staphylococcus epidermidis. Borrero NV; Bai F; Perez C; Duong BQ; Rocca JR; Jin S; Huigens RW Org Biomol Chem; 2014 Feb; 12(6):881-6. PubMed ID: 24389824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]